Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 16;10(8):e037491.
doi: 10.1136/bmjopen-2020-037491.

Patient preferences for asthma management: a qualitative study

Christina Baggott  1 , Amy Chan  2 , Sally Hurford  3 , James Fingleton  3 , Richard Beasley  3 , Matire Harwood  4 , Helen K Reddel  5 , William Mark Magnus Levack  6
Affiliations

Patient preferences for asthma management: a qualitative study

Christina Baggott et al. BMJ Open. .

Abstract

Objective: Preference for asthma management and the use of medications is motivated by the interplay between lived experiences of asthma and patients' attitudes towards medications. Many previous studies have focused on individual aspects of asthma management, such as the use of preventer and reliever inhalers. The aim of this qualitative study was to explore the preferences of patients with mild-moderate asthma for asthma management as a whole and factors that influenced these preferences.

Design: A qualitative study employing qualitative descriptive analysis situated within a constructionist epistemology to analyse transcribed audio recordings from focus groups.

Setting: Three locations within the greater Wellington area in New Zealand.

Participants: Twenty-seven adults with self-reported doctor's diagnosis of asthma, taking short-acting beta-agonists alone or inhaled corticosteroids with or without long-acting beta2-agonist, who had used any inhaled asthma medication within the last month.

Results: Four key areas described preferences for asthma management. Preferences for self-management: participants wanted to be in control of their asthma and developed personal strategies to achieve this. Preferences for the specific medications or treatment regimen: participants preferred regimens that were convenient and reliably relieved symptoms. Preferences for inhaler devices: devices that had dose counters and were easy to use and portable were important. Preferences for asthma services: participants wanted easier access to their inhalers and to be empowered by their healthcare providers. Participant preferences within each of these four areas were influenced by the impact asthma had on their life, their health beliefs, emotional consequences of asthma and perceived barriers to asthma management.

Conclusions: This study illustrates the interaction of the lived experience of asthma, factors specific to the individual, and factors relating to asthma treatments in shaping patient preferences for asthma management. This aids our understanding of preferences for asthma management from the patient perspective.

Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12619000601134).

Keywords: adult thoracic medicine; asthma; qualitative research.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CB reports personal fees from AstraZeneca and Novartis. AC reports grants from Maurice and Phyllis Paykel Trust, Innovate UK, NZPERF, U21, A+Charitable Trust and consultancy fees from Janssen-Cilag, and Spoonful of Sugar Ltd. JF reports grants from Health Research Council of New Zealand, AstraZeneca, GlaxoSmithkline and Genentech; and personal fees and non-financial support from AstraZeneca, GlaxoSmithkline and Boehringer Ingleheim. RB reports grants from Health Research Council of New Zealand, Genentech, AstraZeneca, GlaxoSmithKline; and personal fees from AstraZeneca, Avillion and Theravance. MH reports grants from Health Research Council of New Zealand. HR reports grants from GlaxoSmithKline, AstraZeneca and Novartis; personal fees from AstraZeneca, GlaxoSmithKline, Merck, Novartis, Teva, Sanofi Genzyme and Boehringer Ingelheim; and is chair of the Global Initiative for Asthma scientific committee.

References

    1. O'Conor R, Martynenko M, Gagnon M, et al. . A qualitative investigation of the impact of asthma and self-management strategies among older adults. J Asthma 2017;54:39–45. 10.1080/02770903.2016.1193602 - DOI - PubMed
    1. Oncel S, Ozer ZC, Yilmaz M. Living with asthma: an analysis of patients' perspectives. J Asthma 2012;49:294–302. 10.3109/02770903.2011.642047 - DOI - PubMed
    1. Globe G, Martin M, Schatz M, et al. . Symptoms and markers of symptom severity in asthma—content validity of the asthma symptom diary. Health Qual Life Outcomes 2015;13:21–9. 10.1186/s12955-015-0217-5 - DOI - PMC - PubMed
    1. Svedsater H, Roberts J, Patel C, et al. . Life impact and treatment preferences of individuals with asthma and chronic obstructive pulmonary disease: results from qualitative interviews and focus groups. Adv Ther 2017;34:1466–81. 10.1007/s12325-017-0557-0 - DOI - PMC - PubMed
    1. Steven K, Morrison J, Drummond N. Lay versus professional motivation for asthma treatment: a cross-sectional, qualitative study in a single Glasgow general practice. Fam Pract 2002;19:172–7. 10.1093/fampra/19.2.172 - DOI - PubMed

Publication types

Substances